Mineralys reports positive phase 2 data for lorundrostat in CKD

Mineralys Therapeutics (MLYS) announced positive topline results from its Phase 2 Explore-CKD trial of lorundrostat in hypertension patients with chronic kidney disease, achieving a statistically significant 9.3 mmHg reduction in systolic blood pressure and a 25.6% placebo-adjusted reduction in urine albumin-to-creatinine ratio (UACR). The company, which has a strong cash position despite rapid cash burn, plans to use these results, along with previous trials, to support a New Drug Application for lorundrostat; the stock has experienced volatility recently despite positive year-to-date gains.

Analysis

Mineralys Therapeutics (MLYS) reported successful Phase 2 Explore-CKD trial results for lorundrostat in patients with hypertension and chronic kidney disease (CKD), demonstrating a statistically significant 7.5 mmHg placebo-adjusted reduction in systolic blood pressure (p=0.0024) and a 25.6% placebo-adjusted reduction in urine albumin-to-creatinine ratio (UACR, p=0.0015), a key marker of kidney function. These positive outcomes, marking the fourth successful trial for lorundrostat in hypertension, bolster the drug's profile and are critical for the planned New Drug Application (NDA) package, which will also incorporate data from the pivotal Launch-HTN and Advance-HTN trials. Financially, Mineralys, with a market capitalization of $877 million, maintains a strong liquidity position evidenced by a current ratio of 26.48 and $343 million in cash, exceeding its debt, though it is simultaneously experiencing rapid cash burn to fund its clinical advancements. The company recently reported a Q1 2025 earnings per share loss of $0.79, which favorably surpassed the consensus estimate of a $1.08 loss, and five analysts have revised earnings estimates upward. Despite these positive developments, MLYS stock has exhibited recent volatility, declining 16% over the past week, although it maintains a 10% gain over the past year. Jefferies initiated coverage with a Hold rating and a $15.00 price target, citing potential competition from AstraZeneca, while the upcoming presentation of Phase 3 data at a European hypertension conference will be a significant catalyst for the company's FDA submission process.

Key Decisions for Investors

• Investors should closely monitor the forthcoming Phase 3 trial data for lorundrostat and the subsequent New Drug Application filing, as these represent key inflection points for Mineralys Therapeutics.
• Given the company's strong liquidity (current ratio 26.48, $343M cash) juxtaposed with its rapid cash burn and recent stock volatility (16% decline last week), a thorough assessment of risk tolerance against the drug's potential is advised.
• Factor in the competitive environment, including threats from established players like AstraZeneca, and balance the positive trial data and upward earnings revisions against cautious analyst outlooks, such as Jefferies' Hold rating and $15 price target, when making investment decisions.